Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC38 | TNBC | Basal B | Gefitinib | EGFR | ErbB | 0.0107 | uM | 9453.019 | 0.9991 | 0.9985 | 1.1486 | |
| HCC38 | TNBC | Basal B | Gefitinib | EGFR | ErbB | 0.0533 | uM | 9453.019 | 0.9926 | 0.9871 | 1.1486 | |
| HCC38 | TNBC | Basal B | Gefitinib | EGFR | ErbB | 0.267 | uM | 9453.019 | 0.9774 | 0.9606 | 1.1486 | |
| HCC38 | TNBC | Basal B | Gefitinib | EGFR | ErbB | 1.33 | uM | 9453.019 | 0.9730 | 0.9529 | 1.1486 | |
| HCC38 | TNBC | Basal B | Gefitinib | EGFR | ErbB | 6.67 | uM | 9453.019 | 0.9960 | 0.9931 | 1.1486 | |
| HCC38 | TNBC | Basal B | Gefitinib | EGFR | ErbB | 33.3 | uM | 9453.019 | 0.8488 | 0.7340 | 1.1486 | |
| HCC38 | TNBC | Basal B | Gefitinib | EGFR | ErbB | 0.0000853 | uM | 9469.024 | 1.0497 | 1.0924 | 1.0746 | |
| HCC38 | TNBC | Basal B | Gefitinib | EGFR | ErbB | 0.000427 | uM | 9469.024 | 0.9730 | 0.9497 | 1.0746 | |
| HCC38 | TNBC | Basal B | Gefitinib | EGFR | ErbB | 0.00213 | uM | 9469.024 | 0.9893 | 0.9800 | 1.0746 | |
| HCC38 | TNBC | Basal B | Gefitinib | EGFR | ErbB | 0.0107 | uM | 9469.024 | 0.8941 | 0.8022 | 1.0746 | |
| HCC38 | TNBC | Basal B | Gefitinib | EGFR | ErbB | 0.0533 | uM | 9469.024 | 1.0024 | 1.0045 | 1.0746 | |
| HCC38 | TNBC | Basal B | Gefitinib | EGFR | ErbB | 0.267 | uM | 9469.024 | 1.0177 | 1.0330 | 1.0746 | |
| HCC38 | TNBC | Basal B | Gefitinib | EGFR | ErbB | 1.33 | uM | 9469.024 | 1.0795 | 1.1476 | 1.0746 | |
| HCC38 | TNBC | Basal B | Gefitinib | EGFR | ErbB | 6.67 | uM | 9469.024 | 0.9536 | 0.9134 | 1.0746 | |
| HCC38 | TNBC | Basal B | Gefitinib | EGFR | ErbB | 33.3 | uM | 9469.024 | 0.5639 | 0.1735 | 1.0746 | |
| HCC70 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 0.0000853 | uM | 7856.016 | 1.0181 | 1.0396 | 0.9156 | |
| HCC70 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 0.000427 | uM | 7856.016 | 1.0383 | 1.0838 | 0.9156 | |
| HCC70 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 0.00213 | uM | 7856.016 | 1.0132 | 1.0288 | 0.9156 | |
| HCC70 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 0.0107 | uM | 7856.016 | 1.0703 | 1.1540 | 0.9156 | |
| HCC70 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 0.0533 | uM | 7856.016 | 1.0133 | 1.0290 | 0.9156 | |
| HCC70 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 0.267 | uM | 7856.016 | 0.9702 | 0.9349 | 0.9156 | |
| HCC70 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 1.33 | uM | 7856.016 | 0.9191 | 0.8240 | 0.9156 | |
| HCC70 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 6.67 | uM | 7856.016 | 0.9426 | 0.8749 | 0.9156 | |
| HCC70 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 33.3 | uM | 7856.016 | 0.5908 | 0.1257 | 0.9156 | |
| HCC70 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 0.0000853 | uM | 7857.016 | 1.0058 | 1.0096 | 1.2049 |